Rozel 60mg Injection, containing the active ingredient Denosumab, is a medication primarily used to treat osteoporosis, a condition characterized by weakened bones. It is also prescribed to prevent bone complications in patients suffering from specific cancers, including multiple myeloma and bone metastases. The mechanism of action for Rozel 60mg Injection involves inhibiting a protein known as RANK ligand, which plays a pivotal role in the breakdown of bone tissue. Studies have demonstrated its ability to significantly increase bone density, thereby reducing the risk of fractures in postmenopausal women with osteoporosis and in patients experiencing cancer-related bone loss. For individuals with moderate renal impairment, close monitoring of renal function may be necessary during treatment.
Rozel 60mg Injection is contraindicated in individuals with known hypersensitivity or allergic reactions to any of its components. Adequate calcium and vitamin D supplementation are essential throughout the treatment period. This medication is not approved for use in children and adolescents, as its safety and effectiveness in pediatric populations have not been established, making its use contraindicated in individuals under 18 years of age. Furthermore, it should be used with caution in individuals with pre-existing hypoparathyroidism, a condition characterized by low parathyroid hormone levels.